The preferred medicine active constituent is gliclazide.
药物活性成分优选格列齐特。
Objective To study the relative bioavailability of gliclazide in healthy volunteers.
目的研究格列齐特片的健康人体药物动力学及相对生物利用度。
The top 3 hypoglycemic drugs in respect of sales amount were acarbose, gliclazide, and glipizide.
用药金额排名前3位的药物是阿卡波糖、格列齐特、格列吡嗪。
Conclusion Controlled-release-gliclazide had the similar effect on the patients with type 2 diabetes as ordinary gliclazide tablets did in improving their clinical manifestation and quality of life.
结论格列齐特控释片治疗2型糖尿病的临床疗效和对生存质量的影响与格列齐特普通片相似。
Objective: To study the quality specification of Gliclazide Sustained-release Tablet.
目的:对格列齐特缓释片进行质量标准研究。
Methods 56 patients with IR and fat metabolism disorder were randomly given oral dimethyldiguanide (group A) and Gliclazide capsule (group B) for 3 months.
方法将符合IR及脂代谢紊乱诊断的2型糖尿病患者56例随机分别予口服二甲双胍(A组)、格列齐特(B组)治疗3个月。
The synthesis of key intermediate of Gliclazide can be improved by using Potassium borohydride instead of Lithium aluminum hydride. The procedure is suitable for industrial production.
本文对格列其特的中间体氮杂双环盐酸盐的合成工艺进行了改进,使工艺更适合工业化大生产的要求。
The synthesis of key intermediate of Gliclazide can be improved by using Potassium borohydride instead of Lithium aluminum hydride. The procedure is suitable for industrial production.
本文对格列其特的中间体氮杂双环盐酸盐的合成工艺进行了改进,使工艺更适合工业化大生产的要求。
应用推荐